Exit of AMW GmbH: UVC Partners successfully exits as AMW welcomes new majority shareholders

Warngau, Germany – March 5, 2026 – UVC Partners has successfully exited its investment in AMW GmbH, a specialty pharmaceutical company focused on biodegradable controlled-release drug delivery systems. The exit follows a change in AMW’s shareholder structure, with Ren Life Sciences and Juno Capital Partners joining as new majority shareholders to accelerate the company’s long-term global growth strategy.

UVC Partners first invested in AMW in 2014, leading a financing round alongside BayBG and bmp Ventures with IBG funds with existing investors like SHS Capital and Bayern Capital joining. Over the course of UVC Partners’ investment period, AMW has consistently expanded its product pipeline, strengthened its manufacturing capabilities, and established itself as a leading specialist in biodegradable controlled-release drug delivery systems.

Ren Life Sciences, a life-sciences investment firm focused on advancing European biotech and pharma innovation, and Juno Capital Partners, a Toronto-based pharmaceutical investment company, have taken over the shares held by the previous shareholder group. Existing investors SHS Capital and AMW Evolution will remain invested, ensuring continuity and alignment with management in the next stage of AMW’s expansion.

“We are delighted to welcome our new partners. Bringing Ren Life Sciences and Juno Capital Partners on board, and continuing our partnership with SHS Capital, is the perfect set-up for securing our long-term growth,” said Philipp Karbach, CEO and shareholder of AMW GmbH. “After another year of record sales in 2025, I am excited to partner with their seasoned teams to take even bigger steps towards becoming a global leader in the development, manufacturing and distribution of biodegradable controlled-release drug delivery systems. I would like to express my sincere gratitude to our departing investors, and to our longstanding financing partners such as the European Investment Bank (EIB), who have supported AMW with full commitment over the past years and significantly contributed to shaping the Company.”

“UVC Partners invested in AMW at an early stage and supported its development into a globally active specialty pharmaceutical company. Welcoming new majority shareholders is the right next step to accelerate AMW’s international growth, making this exit a highly successful outcome for UVC Partners’ portfolio”, said Dr. Ingo Potthof, Managing Partner at UVC Partners. “Under CEO Philipp Karbach’s leadership, AMW has successfully transformed from a research-driven organization into a profitable, high growth international pharma player.”

For UVC Partners, the exit marks another successful outcome within its B2B-Tech portfolio, underlining the firm’s focus on supporting European technology companies scaling globally.

‍

About AMW GmbH‍

AMW GmbH isa specialty pharmaceutical company focused on biodegradable implants, providing patients and partners access to value-added medicines for improved adherence and cost-effective therapies. The Company covers the entire value chain, from(co-)development to manufacturing and international commercialization.

AMW GmbH has two approved pharmaceutical products: implants releasing goserelin or leuprorelin respectively, which are distributed worldwide via direct sales and out-licensing. In Germany, leuprorelin is marketed as Leugon® by AMW’s fully owned subsidiary Endomedica GmbH. Based on its unparalleled expertise informulation development, the Company collaborates with pharma and biotech partners worldwide to develop and manufacture high-quality products and life-cycle solutions. AMW GmbH is based in Warngau near Munich, Germany.

For more information, visit www.amw-pharmaceuticals.com

‍

About UVC Partners

UVC Partners is a leading venture capital firm investing in European B2B tech startups, with offices in Munich and Berlin. Managing over €600 million in assets, UVC Partners typically invests between €1million and €10 million initially, with up to €30 million per startup, focusing on DeepTech, ClimateTech, Mobility, and Software/AI. As an independent partner of UnternehmerTUM – Europe’s leading startup ecosystem – UVC Partners has unique access to proprietary deal flow, over 1,000 corporates and SMEs, and top talent from the Technical University of Munich, one of Europe’s leading technical universities. UVC Partners' portfolio includes Flix, Isar Aerospace, planqc, Proxima Fusion, Reverion, Tacto, TWAICE, DeepDrive, STABL, and many more. All portfolio companies and founders benefit from the team’s extensive investment and exit experience, its ability to build sustainable industry leaders, and theUnternehmerTUM network – particularly when it comes to accelerating market entry.

Website: www.uvcpartners.com